INMD

Q: What is the price of InMode (INMD) today?

The current price of InMode (INMD) is $ 13.74, representing a -3.44% gain over the past year. The stock began the year trading around $ 14.69 and is currently priced at $ 13.74. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

Q: When does InMode (INMD) pay dividends?

InMode (INMD) did not pay dividends over the past year.

Q: Is InMode (INMD) a good investment?

InMode (INMD) is currently trading at $ 13.74 with a P/E ratio of 9.93. This represents a 1,081% premium compared to its historical average P/E. Over the past year, the stock has gained -3.44 and paid $ 0.00 in dividends, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was -3.44%.Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

InMode Ltd.

Price

$ 13.74

return (12m)

-3.44%

p/e

9.93

p/bv

1.31

DIVIDEND YIELD

0.00%

INMD price

InMode

If you had invested

exposure

years ago

7 days

30 days

6 months

YTD

1 year

5 years

10 years

15 years

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment INMD

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-4.58%

3 months

-3.24%

1 year

-3.44%

2 years

-25.65%

5 years

-67.43%

10 years

0.00%

Fundamentals INMD

review the fundamentals of InMode shares

P/E

9.93

Sector: -1.47 Industry: 1.03

P/S (PSR)

2.31

Sector: 1.98 Industry: 2.52

P/BV

1.31

Sector: 2.13 Industry: 2.44

DIVIDEND YIELD (DY)

0.00%

Sector: - Industry: -

ROA

11.61%

Sector: -27.33% Industry: -26.11%

ROE

13.18%

Sector: -32.66% Industry: -35.46%

ROIC

16.72%

Sector: -443.10% Industry: -95.45%

NET MARGIN

23.27%

Sector: -29.25% Industry: -31.02%

GROSS MARGIN

77.84%

Sector: 45.57% Industry: 50.25%

OPERATING MARGIN

21.31%

Sector: -23.93% Industry: -27.53%

EV/EBITDA

10.75

Sector: 0.03 Industry: 0.88

EV/EBIT

10.84

Sector: -1.26 Industry: 0.15

PRICE-TO-ASSETS

1.15

Sector: 1.17 Industry: 1.33

BVPS

10.50

Sector: 3.92 Industry: 5.07

EPS

1.38

Sector: -0.90 Industry: -0.69

EQUITY-TO-ASSETS RATIO

0.88

Sector: 0.44 Industry: 0.46

LIABILITIES / ASSETS

0.12

Sector: 0.47 Industry: 0.51

CAGR REVENUE 5 YEARS

0.94%

Sector: - Industry: -

CAGR PROFIT 5 YEARS

-11.98%

Sector: - Industry: -

FAIR VALUE OF InMode ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$ 13.74

Fair Value

$ 0.00

Upside/Downside Return potential.

31.41%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals INMD

DRAG THE FRAME TO SEE MORE DATA

Stock Comparison Tool

DRAG THE FRAME TO SEE MORE DATA

	p/e	p/bv	ROE	dy	market cap	net margin
LLY	37.67	30.52	81.02%	0.59%	$ 952.11 B	34.99%
ISRG	52.21	8.84	16.93%	0.00%	$ 155.53 B	28.15%
SNY	7.24	1.29	17.79%	4.99%	$ 108.11 B	14.75%
TMO	24.35	3.20	13.15%	0.39%	$ 166.76 B	15.15%
NVS	21.44	7.45	34.77%	2.04%	$ 290.19 B	23.92%
ABT	24.34	0.00	-%	2.78%	$ 152.79 B	13.91%
MDT	21.86	2.05	9.38%	3.61%	$ 100.84 B	13.00%
GSK	13.07	4.41	33.77%	3.44%	$ 102.50 B	17.79%
CVS	40.49	1.53	3.78%	2.85%	$ 118.72 B	0.72%
BSX	24.23	3.34	13.78%	0.00%	$ 86.38 B	17.29%
TMDX	13.63	4.74	34.80%	0.00%	$ 2.34 B	27.04%
HCA	12.99	-29.64	-228.14%	0.75%	$ 88.27 B	8.89%
IDXX	40.86	28.76	70.38%	0.00%	$ 44.75 B	24.63%
RMD	19.85	4.65	23.41%	1.12%	$ 30.17 B	27.44%
DHR	33.01	2.30	6.97%	0.79%	$ 121.78 B	14.89%
PHG	21.85	1.87	8.56%	3.42%	$ 24.68 B	5.50%
SYK	36.22	5.26	14.52%	1.09%	$ 120.87 B	13.21%
FMS	10.81	0.72	6.71%	3.64%	$ 11.90 B	4.89%
UHS	6.33	1.27	20.00%	0.51%	$ 9.63 B	8.56%

Stock vs Indice Comparison Tool

If you had invested

years ago

2 years

5 years

10 years

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

INMD Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT InMode

InMode Ltd.

Average Investor10 user rating

4.0 (23 people)

United States

18 years

Founded: 2008

2019

Time since IPO - 7 years

311

Employees

InMode Ltd. is an Israel-based company operating in the healthcare sector, within the medical-device industry focused on minimally invasive aesthetic technologies. The company develops energy-based platforms primarily using radiofrequency technology.

Its main areas of activity include:

• Body contouring and fat-reduction technologies.
• Facial rejuvenation and skin remodeling treatments.
• Radiofrequency-assisted medical procedures.
• Devices for dermatology, plastic surgery and aesthetic medicine.

Its portfolio includes platforms such as BodyTite, FaceTite, Morpheus8, AccuTite, EmbraceRF, Votiva and Optimas, designed for a range of clinical and aesthetic applications.

The company operates globally, with distribution across North America, Europe, Asia-Pacific, the Middle East and Latin America. Its structure includes R&D centers, engineering teams, clinical-validation units, regulatory divisions and global sales and training networks.

Industry dynamics affecting InMode include demand for minimally invasive procedures, technological advances in energy-based devices, regulatory requirements, competition with alternative technologies and broader trends in cosmetic medicine.

Shares of InMode Ltd. trade on the Nasdaq under the ticker INMD.

History and Development

InMode was founded in 2008 in Israel, focusing on the development of radiofrequency-based technologies for minimally invasive medical procedures.

In its early years, the company concentrated on refining radiofrequency-assisted lipolysis (RFAL), enabling controlled fat reduction combined with tissue contraction.

Throughout the 2010s, InMode expanded its product portfolio to include solutions for facial rejuvenation, body sculpting and dermatological treatments, supporting its international growth.

The company strengthened its distribution network and invested in clinical validation to support adoption among physicians and aesthetic practitioners.

In 2019, InMode completed its initial public offering (IPO) on the Nasdaq, expanding its capital base and accelerating research, development and commercialization efforts.

In recent years, the company has operated in a context of rising demand for minimally invasive procedures, expanding its product offerings and enhancing training programs for clinicians.

Additional Information

InMode Ltd. (United States) is listed on the Nasdaq and has a market capitalization of $865.62 Millions, with shareholders equity totaling $661.25 Millions.

The company employs approximately 311 people and operates in the Health sector, within the Medical Supplies and Equipment industry.

Over the past 12 months, InMode Ltd. reported $374.64 Millions in revenue, generating net income of $87.18 Millions.

Key financial metrics include a P/E ratio of 9.93, a price-to-book (P/B) ratio of 1.31, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker INMD.

Market cap

$ 865.62 Millions

Net worth

$ 661.25 Millions

$ 661,250,000.00

Assets

$ 750.84 Millions

$ 750,840,000.00

Total Shares Outstanding

63.00 Millions

63,000,000

Average Daily Trading Volume

$ 949.29 Thousand

$ 949,294.00

Sector

Health

Industry

Medical Supplies and Equipment

INMD

INMD revenue and profits

Financial Results INMD

DRAG THE FRAME TO SEE MORE DATA

INMD cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more stocks

CVS - CVS Health

$ 93.26 58,90% (12M)

P/E

40.49

2.85%

ROE

3.78%

P/BV

1.53

CI - Cigna

$ 286.24 --7,00% (12M)

P/E

11.64

2.13%

ROE

15.39%

P/BV

1.79

CNC - Centene

$ 59.14 4,84% (12M)

P/E

-4.52

0.00%

ROE

-29.93%

P/BV

1.35

HUM - Humana

$ 307.95 39,47% (12M)

P/E

32.70

1.15%

ROE

6.06%

P/BV

1.98

SNY - Sanofi

$ 44.29 --7,52% (12M)

P/E

7.24

4.99%

ROE

17.79%

P/BV

1.29

LLY - Eli Lilly

$ 1,065.00 48,20% (12M)

P/E

37.67

0.59%

ROE

81.02%

P/BV

30.52

HCA - HCA Healthcare

$ 394.07 5,54% (12M)

P/E

12.99

0.75%

ROE

-228.14%

P/BV

-29.64

NVS - Novartis

$ 152.01 37,44% (12M)

P/E

21.44

2.04%

ROE

34.77%

P/BV

7.45